TVRD Stock Forecast & Price Target

Tvardi Therapeutics is compelling because its lead asset TTI-101 has already shown human proof-of-concept in HCC, including 18% confirmed partial responses, a 53% disease control rate, and 100% pharmacodynamic response in biopsied pY-STAT3-positive tumors, which supports genuine target engagement in a high-unmet-need setting. The company also retains key regulatory support with FDA Orphan Drug and Fast-Track designations in HCC, while its REVERT Liver Cancer study spans approximately 154 patients across 21 U.S. sites and could materially expand the opportunity if the 2H26 topline readout confirms early signals. TTI-109 further strengthens the story by preserving equivalent systemic exposure to TTI-101 while improving GI tolerability, with diarrhea lasting 0.47 days versus 3.35 days for TTI-101 at near-equivalent doses, positioning the platform for broader development.

Tvardi Therapeutics is burdened by a difficult scientific thesis, as direct STAT3 inhibition has repeatedly struggled with poor selectivity, bioavailability, toxicity, and no FDA-approved precedent, making the platform inherently high risk. Clinical evidence remains fragile because TTI-101 arm discontinuation rates were 56.7% and 62.1% versus 10.3% for placebo, largely due to gastrointestinal adverse events, while the company is concentrated in just two programs, so setbacks in either could materially impair progress. Financially, it had $25 million in cash as of March 31, 2026, enough to fund operations into 4Q26, but with no commercial revenue and likely future dilution, the downside from execution, regulatory, and financing risk is substantial.